On Today’s Soundbite we hear 4th quarter commentary from James Lanthier (CEO, Mindset Pharma inc.).  From strategic partnerships to new gains in the advancement of science the 4th quarter is shaping up to be crucial to a strong start for a very exciting 2023.  Don’t Miss you!
About Mindset Pharma: Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded in 2019 by domain experts in drug development, medicinal chemistry and capital markets, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely. Classic psychedelics will likely be approved for medical use in the near future; however, they are not optimized as pharmaceuticals and cannot be patented as they are in the public domain. Mindset is applying innovative medicinal chemistry to create a pipeline of optimized psychedelic medications with improved efficacy and reduced toxicity. Mindset has developed a patent-pending chemical synthesis process to address a pressing need for scalable, pharmaceutical grade, low-cost psilocybin

Please visit for a Full Profile View of Mindset Pharma Inc. https://theinvestorscoliseum.com/featured-companies/mindset-pharma-inc/

Mindset Pharma Q4 Commentary From CEO, James Lanthier

Value Proposition

The Investors Coliseum was created for the diligent, informed investor. Whether you gather stock, equity, or company information via social media, traditional methods or word of mouth, we will assist in providing our subscribers with quality, timely and accurate information across various industries and sectors that will enhance your understanding and broaden your scope of knowledge.